Back to Search
HIEU HUYNH, MD
MD
Cardiovascular Disease Physician
NPI: 1003938192IndividualAccepts Medicare
Specialties, Licenses & Credentials
Cardiovascular Disease PhysicianPrimary
Internal Medicine — Cardiovascular Disease
Code: 207RC0000X
4301087048(MI)A85410(CA)
Education
MEDICAL COLLEGE OF WISCONSIN
Class of 2002
Research & Publications (20)
Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma.
PMID 19220580·J Cell Mol Med·2009
7-preclinical
RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma.
PMID 18466352·J Cell Mol Med·2009
7-preclinical
Probiotic preparation VSL#3 induces remission in children with mild to moderate acute ulcerative colitis: a pilot study.
PMID 19067432·Inflamm Bowel Dis·2009
8-other
Sorafenib induces growth suppression in mouse models of gastrointestinal stromal tumor.
PMID 19139124·Mol Cancer Ther·2009
7-preclinical
Lactoferrin and desferrioxamine are ineffective in the treatment of Helicobacter pylori infection and may enhance H. pylori growth and gastric inflammation in mice.
PMID 19187488·Lett Appl Microbiol·2009
7-preclinical
Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma.
PMID 18829493·Clin Cancer Res·2008
7-preclinical
Insulin-like growth factor-binding protein 2 secreted by a tumorigenic cell line supports ex vivo expansion of mouse hematopoietic stem cells.
PMID 18369099·Stem Cells·2008
7-preclinical
Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma.
PMID 18490075·J Hepatol·2008
7-preclinical
Ubiquinol-cytochrome-c reductase 7.2 kDa protein of mitochondrial complex III is steroid-responsive and increases in cardiac hypertrophy and hypertension.
PMID 18066099·Can J Physiol Pharmacol·2007
7-preclinical
Targeted inhibition of the extracellular signal-regulated kinase kinase pathway with AZD6244 (ARRY-142886) in the treatment of hepatocellular carcinoma.
PMID 17237274·Mol Cancer Ther·2007
7-preclinical
Bevacizumab and rapamycin inhibit tumor growth in peritoneal model of human ovarian cancer.
PMID 18025280·Mol Cancer Ther·2007
7-preclinical
AZD6244 and doxorubicin induce growth suppression and apoptosis in mouse models of hepatocellular carcinoma.
PMID 17876044·Mol Cancer Ther·2007
7-preclinical
Xenografts of human hepatocellular carcinoma: a useful model for testing drugs.
PMID 16857806·Clin Cancer Res·2006
7-preclinical
2-Chloroethyl-3-sarcosinamide-1-nitrosourea (SarCNU) inhibits prostate carcinoma cell growth via p53-dependent and p53-independent pathways.
PMID 15529313·Cancer·2004
7-preclinical
Extracellular signal-regulated kinase induces cyclin D1 and Cdk-2 expression and phosphorylation of retinoblastoma in hepatocellular carcinoma.
PMID 15547725·Int J Oncol·2004
8-other
Overexpression of tumour suppressor retinoblastoma 2 protein (pRb2/p130) in hepatocellular carcinoma.
PMID 15059924·Carcinogenesis·2004
7-preclinical
Maximum information approach to scale description for affective measures based on the Rasch model.
PMID 12748403·J Appl Meas·2003
4-observational
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 2800 L ST, 6TH FLOOR
SACRAMENTO, CA 95816 - Phone
- (916) 887-4040
Quick Facts
- NPI
- 1003938192
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 1
- Years in Practice
- 24
- Publications
- 20
Are you this provider?
Claim Your Profile